Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 1(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06781567Phase 2Recruiting

Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

Role: lead

NCT04998422Phase 1Recruiting

A Study of HG381 Administered to Patients With Advanced Solid Tumors

Role: lead

NCT03710915Phase 1Terminated

A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma

Role: lead

NCT04977167Phase 1Recruiting

Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

Role: lead

All 4 trials loaded